Roche (SIX:ROG; OTCQX:RHHBY) and its Genentech Inc. unit have disclosed 11 compounds in clinical development for CNS diseases. Through Phase II, molecules are developed either by Roche's Pharma Research & Early Development (pRED) group, or by Genentech Research & Early Development (gRED). Candidates in Phase III and beyond are managed by Roche. (A) Roche has an option to